ConSynance Therapeutics

Private

Rensselaer, New YorkHealthcare & Life Scienceshttps://www.consynance.com/

Last Round

Grant

Apr 15, 2026

Company Overview

ConSynance Therapeutics is a biopharmaceutical company that develops treatments for central nervous system diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

Prader-Willi SyndromePWSrare CNS disordershyperphagia treatmentsmall molecule therapeuticsorphan drugsclinical-stage biotechtriple monoamine reuptake inhibitorCNS drugsneuropsychiatric drugshypothalamic obesityRare Pediatric Disease DesignationRPDDPriority Review VoucherPRVMCHR1 antagonist

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ConSynance Therapeutics Comps

Public and private peers based on sector, stage, and business model.

ConSynance Therapeutics comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

ConSynance Therapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Grant	Apr 15, 2026
Divestiture	Aug 9, 2021

View all Funding Rounds

Key People

Founding team and executive leadership

Shuang Liu

CEO and Founder

Founding Team

ConSynance Therapeutics Investors

Notable investors and investment history

ConSynance Therapeutics investors
Investor	Rounds
Foundation for Prader-Willi Research	Grant

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Mar 1, 2026
Monthly visitors grew 570% MoM to 1.5K.
Jan 1, 2026
Monthly visitors increased 87% MoM.

View all signals

ConSynance Therapeutics Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

ConSynance Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ConSynance Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersRensselaer, New York

Employee Range3

Year Founded2015

Last FundingApr 15, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.